Literature DB >> 31952519

Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coli.

Sandra Ribes1, Christa Arcilla2, Martina Ott2, Sandra Schütze2, Uwe-Karsten Hanisch2, Stefan Nessler2, Roland Nau2,3.   

Abstract

BACKGROUND: Individuals with impaired immunity are more susceptible to infections than immunocompetent subjects. No vaccines are currently available to induce protection against E. coli meningoencephalitis. This study evaluated the potential of poly(I:C) pre-treatment to induce trained immunity. Poly(I:C) was administered as a non-specific stimulus of innate immune responses to protect immunocompetent and neutropenic wild-type mice from a subsequent challenge by the intracranial injection of E. coli K1.
METHODS: Three days prior to infection, mice received an intraperitoneal injection of poly(I:C) or vehicle. Kaplan-Meier survival curves were analyzed. In short-term experiments, bacterial titers and the inflammatory response were characterized in the blood, cerebellum, and spleen homogenates. NK cell subpopulations in the brain and spleen were analyzed by flow cytometry. Numbers of microglia and activation scores were evaluated by histopathology.
RESULTS: Pre-treatment with 200 μg poly(I:C) increased survival time, reduced mortality, and enhanced bacterial clearance in the blood, cerebellum, and spleen at early infection in neutropenic mice. Poly(I:C)-mediated protection correlated with an augmented number of NK cells (CD45+NK1.1+CD3-) and Iba-1+ microglial cells and a higher production of IFN-γ in the brain. In the spleen, levels of CCL5/RANTES and IFN-γ were increased and sustained in surviving poly(I:C)-treated animals for 14 days after infection. In immunocompetent animals, survival time was not significantly prolonged in poly(I:C)-treated animals although poly(I:C) priming reduced brain bacterial concentrations compared with vehicle-injected animals at early infection.
CONCLUSIONS: Pre-treatment with the viral TLR3 agonist poly(I:C) modulated innate immune responses and strengthened the resistance of neutropenic mice against E. coli K1 meningoencephalitis.

Entities:  

Keywords:  CCL5/RANTES; IFN-γ; Inflammatory response; Meningitis; Microglia; NK cell; Poly(I:C); Trained innate immunity

Year:  2020        PMID: 31952519     DOI: 10.1186/s12974-020-1700-4

Source DB:  PubMed          Journal:  J Neuroinflammation        ISSN: 1742-2094            Impact factor:   8.322


  4 in total

1.  The CoV-2 outbreak: how hematologists could help to fight Covid-19.

Authors:  Sara Galimberti; Chiara Baldini; Claudia Baratè; Federica Ricci; Serena Balducci; Susanna Grassi; Francesco Ferro; Gabriele Buda; Edoardo Benedetti; Rita Fazzi; Laura Baglietto; Ersilia Lucenteforte; Antonello Di Paolo; Mario Petrini
Journal:  Pharmacol Res       Date:  2020-05-06       Impact factor: 7.658

2.  Poly(I:C)-Induced Mesenchymal Stem Cells Protect the Kidney Against Ischemia/Reperfusion Injury via the TLR3/PI3K Pathway.

Authors:  Tian Chen; Yamei Jiang; Shihao Xu; Yin Celeste Cheuk; Jiyan Wang; Cheng Yang; Ruiming Rong
Journal:  Front Med (Lausanne)       Date:  2021-11-25

3.  The Antimicrobial Peptide Mastoparan X Protects Against Enterohemorrhagic Escherichia coli O157:H7 Infection, Inhibits Inflammation, and Enhances the Intestinal Epithelial Barrier.

Authors:  Xueqin Zhao; Lei Wang; Chunling Zhu; Xiaojing Xia; Shouping Zhang; Yimin Wang; Huihui Zhang; Yanzhao Xu; Shijun Chen; Jinqing Jiang; Shanqin Liu; Yundi Wu; Xilong Wu; Gaiping Zhang; Yueyu Bai; Hanna Fotina; Jianhe Hu
Journal:  Front Microbiol       Date:  2021-06-10       Impact factor: 5.640

Review 4.  TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection.

Authors:  Allison M Owen; Jessica B Fults; Naeem K Patil; Antonio Hernandez; Julia K Bohannon
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.